We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Research of the EML4-ALK Gene Expression in the Pleural Effusion or Tumor Tissue From Lung Cancer Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2010 by Taipei Medical University WanFang Hospital.
Recruitment status was:  Enrolling by invitation
Sponsor:
ClinicalTrials.gov Identifier:
NCT01257308
First Posted: December 9, 2010
Last Update Posted: December 9, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Taipei Medical University WanFang Hospital
  Purpose
We wants to analyse the EML4-ALK mutation rate in the patients who have non-small cell lung cancer.

Condition
Lung Cancer Patients

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Research of the EML4-ALK Gene Expression in the Pleural Effusion or Tumor Tissue From Lung Cancer Patients

Resource links provided by NLM:


Further study details as provided by Taipei Medical University WanFang Hospital:

Estimated Enrollment: 100
Study Start Date: August 2010
Estimated Study Completion Date: August 2013
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Lung Cancer Patients
Criteria

Inclusion Criteria:

  • 20 or more than 20 years of age
  • The pathological diagnosis confirmed lung cancer
  • Patients have achieved pleural effusion, or surgical biopsy to obtain tumor tissue specimens
  • The patient had signed inform consent

Exclusion Criteria:

  • pleural effusion or tumor tissue can not be obtained
  • the patient is not suitable to join the research according to the judgement by the investigator
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01257308


Locations
Taiwan
Taipei Medical University - WanFang Hospital
Taipei, Taiwan
Sponsors and Collaborators
Taipei Medical University WanFang Hospital
Investigators
Principal Investigator: Hsin-Gjin Eugene Liu Taipei Medical University WanFang Hospital
  More Information

Responsible Party: Hsingjin Eugene Liu, MD PhD, Taipei Medical University WanFang Hospital
ClinicalTrials.gov Identifier: NCT01257308     History of Changes
Other Study ID Numbers: 99047
First Submitted: December 8, 2010
First Posted: December 9, 2010
Last Update Posted: December 9, 2010
Last Verified: December 2010

Keywords provided by Taipei Medical University WanFang Hospital:
lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Pleural Effusion
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Pleural Diseases